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Abstract 
Background: Sympatric existence of Plasmodium falciparum and Plasmodium vivax, and the practice of malaria 
treatment without microscopic confirmation suggest that the accidental treatment of vivax malaria with sulfadoxine–
pyrimethamine (SP) is common.
Methods: In this study, the frequency distribution of alleles associated with SP resistance were analysed among the P. 
vivax infections from malariometric surveys and its association with SP treatment failure in clinical studies in Indonesia. 
The dhfr and dhps alleles were detected using PCR–RFLP method.
Results: Analysis of 159 P. vivax isolates from malariometric surveys and 69 samples from in vivo SP efficacy study 
revealed various the existence of various alleles of the pvdhfr and pfdhps genes including 57L/I, 58R, 61M, and 117N/T. 
Allele 13L of the dhfr gene and 553G of the dhps gene were not detected in any isolates examined in both studies. 
In the dhfr gene, tandem repeat type-A was the major tandem repeat observed in any isolates analysed. In the dhps 
gene, only the 383G allele was observed. Isolates carrying double, triple and quadruple mutants of dhfr gene were 
found in Lampung, Purworejo, Sumba, and Papua. Although this study revealed a wide distribution of dhfr and dhps 
alleles among the P. vivax isolates across a broad geographic regions in Indonesia, impact on SP efficacy was not 
observed in Sumba.
Conclusion: With proper malaria diagnosis, SP may still be used as a rational anti-malarial drug either as a single 
prescription or in combination with artemisinin.
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Background
Sulfadoxine–pyrimethamine (SP), or Fansidar, a com-
bination anti-malarial drug containing the sulfonamide 
antibiotic, sulfadoxine and the antiprotozoal pyrimeth-
amine, has long been used as an anti-malarial drug 
throughout the world. Its easy single-dose prescrip-
tion and relative efficacy has made this combination an 
excellent choice in the treatment of uncomplicated falci-
parum malaria and intermittent presumptive treatment 
in pregnancy (IPTp) in Africa with the advent of chloro-
quine resistance [1]. Nevertheless, the growing parasite 
resistance to this drug has limited its use in many parts of 
the world, including Indonesia.
The molecular basis of parasite resistance to SP has 
been established in Plasmodium falciparum and rodent 
Plasmodium, and various single nucleotide polymor-
phisms (SNPs) in dihydropteroate synthase (dhps) and 
dihydrofolate reductase (dhfr) genes have been linked 
to the resistance [2, 3]. The SP combination has never 
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been recommended to treat vivax malaria in Indone-
sia, however, the sympatric existence of P. falciparum 
and Plasmodium vivax and the practice of malaria 
treatment without microscopic confirmation suggest 
that accidental treatment of vivax malaria with SP has 
often taken place. Treatment of patients with SP has 
inadvertently led to the simultaneous selection of SP-
resistant P. vivax. In Indonesia before 2004, SP was 
used alone as a second-line anti-malarial drug for fal-
ciparum malaria [4]. Although SP has never been rec-
ommended for the treatment of patients with P. vivax 
malaria, the selection pressure exerted by the drug is 
expected to have continued progressively in P. falcipa-
rum and P. vivax [5]. Since 2010, vivax malaria cases in 
Indonesia are treated with artemisinin-based combina-
tion therapy (ACT) [6].
Pyrimethamine inhibits the dhfr enzyme [7] and sul-
fadoxine targets the dhps enzyme in the folate biosyn-
thetic pathway of the parasite [8]. Point mutations in 
parasite dhfr and dhps genes confer resistance to SP in 
P. falciparum. High level resistance to pyrimethamine 
in P. falciparum results from the accumulation of muta-
tions in pfdhfr principally at codons 16, 51, 59, 108, and 
164 [9, 10]. These mutations have been shown to alter 
the pyrimethamine binding sites in pfdhfr and reduce 
enzyme drug interaction [11]. Twenty non-synonymous 
mutations have already been described in the pvdhfr 
gene [5, 12]. Some of these mutations (at codon 57, 58, 
61, 117, and 173) are involved in resistance to pyrimeth-
amine [13, 14]. Five mutations have already been identi-
fied in the pvdhps gene, at codon 382, 383, 512, 553, and 
585, corresponding to position 436, 437, 540, 581, and 
613 of the homologues gene in the P. falciparum [3, 14, 
15]. The pvdhfr and pvdhps genotypes might be associ-
ated with treatment failure in individual vivax malaria 
patients [16]. Limited data are available about polymor-
phisms in pvdhfr and pvdhps genes of malaria parasites 
from Indonesia. Previous data from Lampung show 
triple mutation found in this area [17] and a quadruple 
mutant 49R/57L/58R/61M/117T was found in Papua 
[17, 18].
The extent of genetic polymorphisms associated with 
resistance to SP was screened among the P. vivax iso-
lates in Indonesia towards evaluating the use of SP for the 
treatment of P. vivax malaria and the possible use of SP 
for IPTp.
Methods
Plasmodium vivax isolates were obtained from two dif-
ferent studies: (1) malariometric surveys in five malaria-
endemic areas; and, (2) in  vivo SP efficacy study in 
Southwest Sumba District.
Malariometric survey (sample set 1)
Blood blots on filter paper (3 MM; Whatman, Hillsboro, 
OR, USA) containing approximately 50 µL blood equiva-
lent were collected from five selected malaria-endemic 
areas: Lampung, Purworejo, Mataram, Sumba, and 
Papua (September 2006–August 2008) (Fig. 1).
In vivo sulfadoxine–pyrimethamine efficacy study (sample 
set 2)
The study was conducted in Southwest Sumba District, 
East Nusa Tenggara Province from September 2009 
to February 2010 (Fig.  1). The subjects were recruited 
from a pool of malaria-infected individuals identified 
during an active malariometric survey. Subjects were 
excluded if they met any of the following exclusion 
criteria: (1) were pregnant; (2) history of allergy to the 
study drugs or study drugs’ derivative; (3) completed 
treatment with an anti-malarial drug in the preceding 
2 weeks; or, (4) medical history of untreated hyperten-
sion or chronic heart, kidney or liver disease. Plasmo-
dium vivax-infected subjects did not show any signs 
of severe malaria. All study subjects were supervised 
in their treatment with SP tablets (30  mg sulfadoxine 
and 1.5 mg pyrimethamine per kg body weight, accord-
ing to national treatment guidelines) and followed for 
28  days. A study nurse gave medication, observed and 
recorded all treatments, and repeated the treatment if 
vomiting occurred within 30  min of the administered 
dose. Parasitological responses were classified accord-
ing to criteria set by WHO [19]. At enrolment, a fin-
ger prick was performed to make thick and thin blood 
smears, blots on filter paper (Whatman, Schleicher and 
Schuell, Whatman International Ltd, Maidstone, UK) 
for further parasite genotyping, and haemoglobin meas-
urement using hemocue (HemocueTM Hb201+, Angel-
holm, Sweden). Blood smears and filter-paper blood 
samples were also collected from finger pricks on days 
1, 2, 3, 7, 14, 21, and 28. Smears were read by expert 
microscopists and confirmed by polymerase chain reac-
tion (PCR). Adverse effects observed during the study 
were recorded by the study nurse and/or physician. Pri-
maquine therapy against relapse was not provided until 
discontinuation from the study, i.e., day of recurrence 
or day 28. This study has been approved by the Eijk-
man Institute Research Ethics Committee for the use of 
human subjects.
Malaria microscopy
All blood slide thick and thin blood smears were stained 
with Giemsa, and subsequently examined by light micros-
copy. Parasite density was determined by counting the 
number of parasites per leukocytes in 100-high-power 
Page 3 of 7Asih et al. Malar J  (2015) 14:365 
microscopic fields in a Giemsa-stained thick film, assum-
ing an average of 20 leukocytes/microscopic field and 
8000 leukocytes/µl blood. The total number of parasites/
µl was multiplied by 40 [20].
Genomic DNA preparation
DNA from all samples (including sample set 2, on day of 
enrolment and day of recurrence) were extracted from 
the blood samples using Chelex-100 ion exchanger (Bio-
rad Laboratories, Hercules, CA, USA) [21]. The filter 
papers were placed in a microtube, 100 µl distilled water 
and 50 µl 20 % Chelex-100 in distilled water were added. 
DNA was extracted by boiling at 100 °C for 10 min. The 
extracted DNA was either used immediately for PCR 
assays or stored at −20 °C for later analysis.
Confirmation of Plasmodium vivax species
A nested PCR diagnosis was performed using the 18S 
rRNA gene diagnostic [22] in both sets of sample isolates.
Amplification and analysis of pvdhfr and pvdhps gene 
mutation
The nested PCR amplification strategies for pvdhfr and 
pvdhps genes were designed using previously published 
results [5, 23]. Two fragments were obtained by nested-
PCR: one being used for the analysis of F57L/I, S58R, 
T61M, and S117N/T and the other for the examination of 
I13L, F57L/I, S58R, and T61M alleles. Both pvdhfr gene 
tandem repeat variants [7, 24] were observed and desig-
nated as type A (three tandem repeat GGDN TS GGDN 
TH GGDN) and type B (two tandem repeat GGDN TS 
GGDN and deletion at 98–103 residue). The amplified 
fragment of the pvdhps gene corresponds to GenBank 
acc no. AY186730 and detects mutations A383G and 
A553G [23].
Results
All Plasmodium infection isolates were confirmed as P. 
vivax by PCR diagnosis, performed using 18S rRNA gene 
primer. The analysis of these P. vivax isolates indicated 
that several isolates carried mutant alleles of the Pvdhfr, 
such as 57L/I, 58R, 61M, and 117N/T and allele 383G of 
the Pvdhps genes.
Malariometric survey (sample set 1)
Mutant alleles of the dhfr gene
Of the 159 isolates screened for pvdhfr mutations from 
five different malaria endemic areas, 131 were found 
to carry at least one of the pvdhfr mutant alleles and 
28 isolates (21  %) carried no mutant allele. The allele 
with the highest prevalence was 117N (27  %), followed 
by 117T (18  %). Isolates carried the double mutant 
(58R/117N) were found in three sites: Papua, Lampung 
and Purworejo, with the highest prevalence observed 
in Lampung (23  %). Plasmodium vivax isolates with a 
double mutant dhfr allele were not found in Sumba and 
Mataram. The triple (58R/61M/117T) and quadruple 
(57L/58R/61M/117T) mutant alleles were found with 
prevalences of 3 and 18 %, respectively (Table 1). Muta-
tions at codon I13L were not detected in any of the sam-
ples analysed. Three types of allelic combination of the 
dhfr gene were identified from Papua, while two types 
were identified from Lampung and Purworejo. One type 
of allelic combination was found from Sumba. Tandem 
repeat type A was the major tandem repeat observed 
among the P. vivax isolates in all sites. The frequency 
Fig. 1 The origin of Plasmodium vivax isolate for sample sets 1 and 2. (1) Lampung, south of Sumatera; (2) Purworejo, Central Java; (3) Mataram, West 
Nusa Tenggara; (4) Sumba (East Nusa Tenggara); and, (5) Jayapura, Papua
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distribution of tandem repeat A ranged from 66.7 to 
100 % (Table 1).
Mutant alleles of the dhps gene
Analysis of the 159 P. vivax isolates revealed only one 
mutant allele of the dhps gene, 383G, in three sites 
with prevalence of 33, 15 and 9  % in Papua, Purworejo 
and Sumba, respectively. Mutant allele 553G was not 
observed in any of the isolates examined.
In vivo sulfadoxine–pyrimethamine efficacy study (sample 
set 2)
Of the 500 subjects screened, 69 subjects met the inclu-
sion criteria and were recruited for this study. Charac-
teristic of the subject is shown in Table  2. Sixty-three 
(94 %) subjects were successfully cleared their parasitae-
mia before day 7 and completely recovered up to day 28 
(Table  3). One subject (1.5  %) was found to carry para-
sites at day 14. Three subjects were lost to follow-up and 
two subjects dropped out (Table 3). No severe side effects 
were noted in any of the 69 subjects enrolled.
Mutant alleles of the pvdhfr gene
Various types of allelic combination of dhfr gene mutants 
were identified from in vivo SP efficacy study in Sumba 
(Table 4). Analysis of the pvdhfr gene of the 69 subjects 
at day 0 and one subject at day 14 revealed the existence 
of four mutant alleles: 57L/I, 58R, 61M, and 117N/T, 
either as a single mutation or in combination with the 
Table 1 Prevalence of allelic combinations and repetitive motifs in dhfr gene among Plasmodium vivax isolates in Indo-
nesia
Type Prevalence in malaria-endemic areas (%)
Papua Lampung Purworejo Sumba Mataram
Allelic combination
 58R/117N 11.8 (4/34) 96.3 (26/27) 60 (6/10) 0 (0/60) 0 (0/28)
 58R/61M/117N 2.9 (1/34) 11.1 (3/27) 0 (0/10) 0 (0/60) 0 (0/28)
 57L/58R/61M/117T 61.8 (21/34) 0 (0/27) 10 (1/10) 3.3 (2.60) 0 (0/28)
Repetitive motifs GGDN (units)
 Type A = three units 100 (34/34) 66.7 (18/27) 100 (10/10) 85.7 (24/28) 92.9 (26/28)
 Type B = two units 0 (0/34) 33.3 (9/27) 0 (0/10) 14.3 (4/28) 7.1 (2/28)
Table 2 Characteristics of the subjects at enrolment in the 
28 days in vivo sulfadoxine–pyrimethamine test in Sumba
Number of subjects 69
Median (range) age (year) 13.2 (2–60)
Median (range) haemoglobin level (day 0) (g/dl) 13.2 (9.4–16.2)
Geometric mean asexual parasitaemia/µl blood 893 (40–19,600)
Table 3 Plasmodium vivax phenotyping sulfadoxine–
pyrimethamine in Sumba
ETF early treatment failure, LTF late treatment failure, ACPR adequate clinical 
parasitological response, LTFU lost to follow-up
a Day 14
Total subject ETF LTF ACPR LTFU Drop-out
69 0 1a 63 3 2
Table 4 Allelic combination in dhfr and dhps genes among 
the sulfadoxine–pyrimethamine efficacy samples
Total isolates = 70; 69 isolates D0; 1 isolate DR
a For recurrence isolate, genotype day 0 = day 14
Type of allelic combination Total 
isolate
F57I/L S58R T61M S117T/N A383G
F R M S A 13a
F R M T G 11
L R M S G 8
F S M S G 6
L R M T A 5
F R M T A 3
F R M N A 3
F R M S G 3
F S M T A 3
L R M S A 2
F S T N G 2
F S M S A 1
L S M T G 1
L S T S A 1
F R T N A 1
L R T N G 1
F S T T A 1
L S M T A 1
F S M T G 1
L R M T G 1
F S M N A 1
F R M N G 1
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other alleles. A single mutation at codon 57L, 61M, 
117N, and 117T was found with frequencies of 1.4, 8.6, 
2.8, and 1.4 %, respectively. Allele I13L was not detected 
in any of the isolates examined. Double mutants with 
four types of allelic combination (58R/61M, 58R/117N, 
61M/117T, 61M/117N) were found in 24 isolates (34.3 %) 
including the recurrent isolate at day 14. Triple mutants 
with five types of allelic combination (58R/61M/117T, 
57L/58R/61M, 58R/61M/117N, 57L/61M/117T, and 
57L/58R/117N) were observed in 27 isolates (38.6  %). 
The quadruple mutant, 57L/58R/61M/117T, was found 
in one isolate (1.4  %). Tandem repeat type A was also 
the major tandem repeat observed in isolates analysed, 
including the recurrent isolate at day 14.
Mutant alleles of the pvdhps gene
Analysis of the pvdhps gene of the 70 subjects revealed 
only one mutant allele, 383G in 35 subjects (50 %). The 
recurrent isolates at day 14 carried no mutant alleles of 
the dhps gene.
Discussion
Analysis of the pvdhfr and pvdhps genes in P. vivax iso-
lates from five different malaria-endemic areas in Indo-
nesia revealed a wide distribution of the mutant alleles 
associated with resistance to SP. The mutant alleles of 
the dhfr gene were found either as single polymorphisms 
or in combination with other polymorphisms. With the 
dhps gene, 383G was the only mutant allele observed. 
Previous reports found similar polymorphisms in P. vivax 
isolates from Lampung and Papua [17, 18]. The find-
ings indicate that the SP drug pressure to P. vivax may 
have taken place at all sites and that mistreatment of P. 
vivax malaria infections may be widespread. Until 2010, 
the recommended drug for vivax malaria was the com-
bination of chloroquine with primaquine but due to the 
spread of chloroquine resistance to P. falciparum and P. 
vivax, ACT was introduced [24].
Three types of allelic combination of pvdhfr gene were 
observed among the P. vivax isolates from the five malaria-
endemic areas investigated. These included double, tri-
ple and quadruple mutants. Overall, when looking at the 
allelic combinations, the frequency of double mutants was 
22.6 % (36 isolates), triple mutants was 2.5 % (four isolates) 
and quadruple mutants was 15.1 % (24 isolates). Plasmo-
dium vivax isolates from Papua were dominated by quad-
ruple mutants (61.8 %). Nevertheless, the in vivo study in 
Sumba to determine the molecular basis of SP treatment 
failure in P. vivax indicated that all P. vivax isolates that 
carried the aforementioned allelic combination were still 
susceptible to SP, except in one recurrent isolate at day 14 
with the double dhfr mutants, 58R/61M.
Mutations in pvdhfr and dhps genes, including 58R and 
117N, have been implicated in pyrimethamine and sulf-
adoxine resistance, respectively [25]. In P. falciparum, 
the existence of quintuple mutations, three in dhfr gene 
(S118N, C59R and N51C) and two in dhps gene (A437G 
and K540E), have been associated with SP treatment fail-
ure [26–28]. The corresponding mutations in P. vivax 
are 117N, 58R and 49R in dhfr gene and 383G and 553G 
in dhps gene. Although dhfr mutations have been wide-
spread among the P. vivax isolates, mutations at the dhps 
gene are still rare. The 383G allele was found in various 
frequency among the isolates examined and the highest 
frequency was observed in Purworejo.
Two and three GGDN repeat units were detected in 
wild and mutant types dhfr in all allelic combination. This 
result corroborates the previous results where an inser-
tion/deletion event within the short repetitive region did 
not appear to be clearly associated with antifolate resist-
ance. However, repetitive sequences that produce length 
polymorphism may not affect pyrimethamine sensitivity 
[24].
The wide distribution of dhfr and dhps gene polymor-
phisms among the P. vivax field isolates seems to have 
little implication on the efficacy of SP combination treat-
ment. This was demonstrated in the in vivo study in west 
Sumba District, where the efficacy of SP was still very 
high (94  %). This is the first report from Indonesia that 
demonstrates that P. vivax is highly sensitive to SP. The 
results of this study however require further observation 
in areas where SP was reported to be resistant to P. falci-
parum, such as Papua [18]. Unfortunately, with current 
policy that adopted ACT as first-line therapy for both 
P. vivax and P. falciparum, it will be difficult to justify a 
study to monitor the efficacy of SP anymore. Neverthe-
less, SP may be considered as a rational option for the 
treatment of vivax malaria either given alone or in com-
bination with artemisinin. Previous studies in Pakistan 
and Afghanistan also found high efficacy of SP in the 
treatment of vivax malaria [29].
Most subjects carried triple and quadruple mutations 
in the dhfr gene in addition to the mutaion in dhps 383G, 
but still were sensitive to the SP. The only subject who 
showed late treatment failure carried the double muta-
tions in dhfr without any dhps gene mutation. Here, it is 
not clear as to whether this parasite originated from new 
infection or was a recurrence from the current infection, 
keeping in mind that previous results indicate that hyp-
nozoites may have a different genotype than that of the 
initial infection [30, 31]. Nonetheless, as SP has a long 
half-life, any parasite that was detected during the moni-
tored 42-day treatment should be relatively resistant to 
SP. Previous results from Thailand also show inconclusive 
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results upon the association between the dhfr and dhps 
mutations to the SP treatment outcome. Although it is 
clear that the isolates that carry multiple mutations in 
dhfr and dhps are associated with high grade SP resist-
ance, many of the isolates still respond adequately to 
the SP [23]. In this regard, it is important to note that in 
Indonesia, the proportion of P. vivax isolates that carry 
double mutant dhps is still very rare and in fact was only 
reported in the isolates collected from northeastern 
Papua. Papua, with the highest amount of malaria and 
consequent highest selection pressure from mistreatment 
of vivax infections with SP, may explain this high num-
ber of multiple resistant alleles. These results may explain 
why the P. vivax isolates in Sumba are still susceptible to 
SP and this also may be true of the isolates from Lam-
pung, Purworejo, Mataram and, to a lesser extent, in 
Papua.
The development and spread of drug-resistant para-
site strains is a major obstacle to the malaria control 
and elimination programme. As the molecular basis of 
the parasite resistance to antifolates and sulfa drugs has 
been well established in Plasmodium spp., analysis on the 
frequency distribution of dhfr and dhps mutant alleles 
would provide a better perspective on the use of SP in a 
particular area. In this regard, it is important to notice an 
increasing prevalence of P. vivax isolates carrying the tri-
ple mutants of dhfr gene in all sites and particularly the 
quadruple mutants of dhfr gene in northeastern Papua 
regions.
Conclusions
This study revealed a wide distribution of dhfr and dhps 
mutant alleles among P. vivax isolates across broad 
geographic regions of Indonesia, but an impact on the 
SP efficacy was not observed at this point. Therefore, 
with proper malaria diagnosis, SP may still be used as a 
rational anti-malarial drug, either as a single prescription 
or in combination with artemisinin.
Authors’ contributions
PBSA and DS conceived the study, and participated in its design and drafted 
the first manuscript. PBSA, SSM, RN, WS, RMD, S, AST, and M assisted in field 
work. IER was engaged in data collection, cleaning, analysis and contributed 
to data interpretation. PBSA, SSM and RN performed the PCR with input from 
PBSA. PBSA and DS supervised the laboratory procedures and PCR qual-
ity control. DS, NFL and RWS oversaw the study design and provided input 
to data analysis, interpretation and helped check the draft manuscript. All 
authors contributed to submitted version of the manuscript. All authors read 
and approved the final manuscript.
Author details
1 Eijkman Institute for Molecular Biology, Jalan Diponegoro 69, Jakarta 10430, 
Indonesia. 2 Eck Institute for Global Health, University of Notre Dame, Notre 
Dame, IN, USA. 3 Department of Biomedicine and Pharmacology, National 
Institute for Health Research and Development, Jakarta, Indonesia. 4 Immu-
nobiology Laboratory, School of Medicine, University of Mataram, Mataram, 
Indonesia. 5 West Nusa Tenggara Hepatitis Laboratory, Mataram, Indonesia. 
6 Department of Medical Microbiology, Radboud University Nijmegen Medical 
Centre, Nijmegen, The Netherlands. 7 Department of Parasitology, Faculty 
of Medicine, Hasanuddin University, Makasar, Indonesia. 
Acknowledgements
Samples collection in Lampung, Purworejo and Mataram were supported by 
Research Grant from The Ministry of Research and Technology, Republic of 
Indonesia, through Eijkman Institute for Molecular Biology, Jakarta. Sample 
collection in Sumba, Papua and molecular assays for all samples collected 
were supported by a Grant-InAid from The Netherlands Foundation for the 
Advancement of Tropical Research, The Netherlands Foundation for Health 
Research and Development through PRIOR Programme Project-11. The 
authors are grateful to individuals who participated in this study. We thank 
the Eijkman Institute for Molecular Biology, Jakarta, professional staff at 
Department of Health Jakarta, US NAMRU-2 Jakarta, Provincial Health Depart-
ment, District Health Department and Puskesmas at study sites in Lampung, 
Purworejo, Mataram, Sumba and Papua, for the support, encouragement and 
help with sample collection.
Compliance with ethical guidelines
Competing interests
The authors declare that they have no competing interests.
Received: 29 June 2015   Accepted: 12 September 2015
References
 1. WHO. Strategic framework for malaria prevention and control during 
pregnancy in the Africa Region. World Health Organization, Regional 
Office for Africa, Brazzaville, AFR/MAL/04/01. 2004.
 2. Foote SJ, Galatis D, Cowman AF. Amino acids in the dihydrofolate 
reductase-thymidylate synthase gene of Plasmodium falciparum involved 
in cycloguanil resistance differ from those involved in pyrimethamine 
resistance. Proc Natl Acad Sci USA. 1990;87:3014–7.
 3. Triglia T, Cowman AF. Primary structure and expression of the dihydrop-
teroate synthetase gene of Plasmodium falciparum. Proc Natl Acad Sci 
USA. 1994;91:7149–53.
 4. Ministry of Health, Republic of Indonesia: Bulletin Kesehatan. Buku saku 
pedoman pengobatan malaria di Indonesia. 2004.
 5. Imwong M, Pukrittayakamee S, Rénia L, Letourneur F, Charlieu JP, Leart-
sakulpanich U, et al. Novel point mutations in the dihydrofolate reductase 
gene of Plasmodium vivax: evidence for sequential selection by drug 
pressure. Antimicrob Agents Chemother. 2003;47:1514–21.
 6. Ministry of Health, Republic of Indonesia: Bulletin Kesehatan. Buku saku 
pedoman pengobatan malaria di Indonesia. 2010.
 7. De Pécoulas PE, Tahar R, Ouatas T, Mazabraud A. Sequence variations 
in the Plasmodium vivax dihydrofolate reductase-thymidylate synthase 
gene and their relationship with pyrimethamine resistance. Mol Biochem 
Parasitol. 1998;92:265–73.
 8. Triglia T, Menting JG, Wilson C, Cowman AF. Mutations in dihydropter-
oate synthase are responsible for sulfone and sulfonamide resistance in 
Plasmodium falciparum. Proc Natl Acad Sci USA. 1997;94:13944–9.
 9. Auliff A, Wilson DW, Russell B, Gao Q, Chen N, Anh LN, et al. Amino acid 
mutations in Plasmodium vivax dhfr and dhps from several geographi-
cal regions and susceptibility to antifolate drug. Am J Trop Med Hyg. 
2006;75:617–21.
 10. Sibley CH, Hyde JE, Sims PF, Plowe CV, Kublin JG, Mberu EK, et al. 
Pyrimethamine–sulfadoxine resistance in Plasmodium falciparum: what 
next? Trends Parasitol. 2001;17:582–8.
 11. Yuvaniyama J, Chitnumsub P, Kamchonwongpaisan S, Vanichtanankul 
J, Sirawaraporn W, Taylor P, et al. Insights into antifolate resistance from 
malarial DHFR-TS structures. Nat Struct Biol. 2003;10:357–65.
 12. Hawkins VN, Auliff A, Prajapati SK, Rungsihirunrat K, Hapuarachchi HC, 
Maestre A, et al. Multiple origins of resistance-conferring mutations in 
Plasmodium vivax dihydrofolate reductase. Malar J. 2008;7:72.
 13. Hawkins VN, Joshi H, Rungsihirunrat K, Na-Bangchang K, Sibley CH. 
Antifolates can have a role in the treatment of Plasmodium vivax. Trends 
Parasitol. 2007;23:213–22.
Page 7 of 7Asih et al. Malar J  (2015) 14:365 
 14. Imwong M, Sudimack D, Pukrittayakamee S, Osorio L, Carlton JM, Day 
NPJ, et al. Microsatellite variation, repeat array length, and population 
history of Plasmodium vivax. Mol Biol Evol. 2006;23:1016–8.
 15. Hawkins VN, Suzuki SM, Rungsihirunrat K, Hapuarachchi HC, Maestre A, 
Na-Bangchang K, et al. Assessment of the origins and spread of putative 
resistance-conferring mutations in Plasmodium vivax dihydropteroate 
synthase. Am J Trop Med Hyg. 2009;81:348–55.
 16. Kaura S, Prajapatib SK, Kalyanaramana K, Mohmmeda A, Joshib H, Chau-
han VS. Plasmodium vivax dihydrofolate reductase point mutations from 
the Indian subcontinent. Acta Trop. 2006;97:174–80.
 17. Hastings MD, Porter KM, Maguire JD, Susanti I, Kania W, Bangs MJ, et al. 
Dihydrofolate reductase mutations in Plasmodium vivax from Indonesia 
and therapeutic response to sulfadoxine plus pyrimethamine. J Infect Dis. 
2004;189:744–50.
 18. Tjitra E, Baker J, Suprianto S, Cheng Q, Anstey NM. Therapeutic efficacies 
of artesunate–sulfadoxine–pyrimethamine and chloroquine–sulf-
adoxine–pyrimethamine in vivax malaria pilot studies: relationship 
to Plasmodium vivax dhfr mutations. Antimicrob Agents Chemother. 
2002;46:3947–53.
 19. WHO. Monitoring antimalarial drug resistance. Report of a WHO consulta-
tion. World Health Organization, Geneva, Switzerland. 2002.
 20. Gilles HM. Diagnostic method in malaria. In: Gilles HM, Warrel DA, editors. 
Bruce-Chwatt’s essential malariology. New York: Oxford University Press; 
1993. p. 79–95.
 21. Wooden J, Kyes S, Sibley CH. PCR and strain identification in Plasmodium 
falciparum. Parasitol Today. 1993;9:303–5.
 22. Singh B, Bobogare A, Cox-Singh J, Snounou G, Abdullah MS, Rahman 
HA. A genus- and species-specific nested polymerase chain reaction 
malaria detection assay for epidemiologic studies. Am J Trop Med Hyg. 
1999;60:687–92.
 23. Imwong M, Pukrittayakamee S, Cheng Q, Moore C, Looareesuwan 
S, Snounou G, et al. Limited polymorphism in the dihydropteroate 
synthetase gene (dhps) of Plasmodium vivax isolates from Thailand. 
Antimicrob Agents Chemother. 2005;49:4393–5.
 24. Asih PBS, Syafruddin D, Leake J, Sorontou Y, Sadikin M, Sauerwein RW, 
et al. Phenotyping clinical resistance to chloroquine in Plasmodium 
vivax in Northeastern Papua, Indonesia. Int J Parasitol Drugs Drug Resist. 
2011;1:28–32.
 25. Rungsihirunrat K, Harnyuttanakorn P, Siripoon N, Seugorn A, Pumpi-
boon T, Thaithong S. Sequence variations of the Plasmodium vivax 
dihydrofolate reductase gene from Thai isolates. J Trop Med Parasitol. 
2003;26:1–8.
 26. Rungsihirunrat K, Sibley CH, Mungthin M, Na-Bangchang K. Geographi-
cal distribution of amino acid mutations in Plasmodium vivax DHFR 
and DHPS from malaria endemic areas of Thailand. Am J Trop Med Hyg. 
2008;78:462–7.
 27. Basco LK, Tahar R, Ringwald P. Molecular basis of in vivo resistance to 
sulfadoxine–pyrimethamine in African adult patients infected with 
Plasmodium falciparum malaria parasites. Antimicrob Agents Chemother. 
1998;42:1811–4.
 28. Jelinek T, Kilian AH, Kabagambe G, von Sonnenburg F. Plasmodium falci-
parum resistance to sulfadoxine/pyrimethamine in Uganda: correlation 
with polymorphisms in the dihydrofolate reductase and dihydropteroate 
synthetase genes. Am J Trop Med Hyg. 1999;61:463–6.
 29. Leslie T, Mayan MI, Hasan MA, Safi MH, Klinkenberg E, Whitty CJM, et al. 
Sulfadoxine–pyrimethamine, chlorproguanil-dapsone, or chloroquine for 
the treatment of Plasmodium vivax malaria in Afghanistan and Pakistan. 
JAMA. 2007;297:2201–9.
 30. Chen N, Auliff A, Rieckmann K, Gatton M, Cheng Q. Relapses of Plasmo-
dium vivax infection result from clonal hypnozoites activated at predeter-
mined interval. J Infect Dis. 2007;195:934–41.
 31. Imwong M, Snounou G, Pukrittayakamee S, Tanomsing N, Kim JR, Nandy 
A, et al. Relapses of Plasmodium vivax infection usually result from activa-
tion of heterologous hypnozoites. J Infect Dis. 2007;195:927–33.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
